Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 211-218

  Pujol, Jean Louis ^a   Pirker, Robert ^b   Lynch, Thomas J ^c   Butts, Charles A ^d   Rosell, Rafael ^e   Shepherd, Frances A ^f   Vansteenkiste, Johan ^g   O'Byrne, Kenneth J ^h   de Blas, Barbara ⁱ   Heighway, Jim ^j   von Heydebreck, Anja ⁱ   Thatcher, Nick ^k  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c YALE CANCER CENTER   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h ST JAMES S HOSPITAL   (Ireland)

ⁱ MERCK KGAA   (Germany)

^j Cancer Communications and Consultancy Ltd   (United Kingdom)

^k CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Cetuximab; Chemotherapy; First line; Meta analysis; NSCLC; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS;

CETUXIMAB; CHEMOTHERAPY; FIRST-LINE; META-ANALYSIS; NSCLC; TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84892844284     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.006     Document Type: Article

References (39)

1. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
2. Makitaro R., Paakko P., Huhti E., Bloigu R., Kinnula V.L. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J 2002, 19:1087-1092.
3. Potosky A.L., Saxman S., Wallace R.B., Lynch C.F. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004, 22:3261-3268.
4. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
5. Bunn P.A., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 2008, 13(Suppl. 1):37-46.
6. Ramalingam S., Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008, 13(Suppl. 1):5-13.
7. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
8. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
9. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
10. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
11. Soria J.C., Mauguen A., Reck M., Sandler A.B., Saijo N., Johnson D.H., et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013, 24:20-30.
12. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
13. Bunn P.A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 2002, 20:23S-33S.
14. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70.
15. Grossi F., Aita M., Defferrari C., Rosetti F., Brianti A., Fasola G., et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009, 14:497-510.
16. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
17. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. J Am Med Assoc 2004, 292:470-484.
18. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
19. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
20. Stewart L.A., Tierney J.F. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002, 25:76-97.
21. Pignon J.P., Auperin A., Borget I., Hill C. Role of meta-analyses and of large randomized trials in the study of cancer treatments. Lung Cancer 2009, 65:9-12.
22. Butts C.A., Bodkin D., Middleman E.L., Englund C.W., Ellison D., Alam Y., et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2007, 25:5777-5784.
23. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
24. TNM Classification of Malignant Tumours 2002, 99-103. Wiley-Liss, New York. 6th ed. L.H. Sobin, C. Wittekind (Eds.).
25. Whitehead A. Meta-analysis of controlled clinical trials 2002, John Wiley & Sons Ltd., Chichester, 57-61, 88-91.
26. Lin H., Jiang J., Liang X., Zhou X., Huang R. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010, 70:57-62.
27. Chen P., Wang L., Liu B., Zhang H.Z., Liu H.C., Zou Z. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 2011, 67:235-243.
28. Ibrahim E.M., Abouelkhair K.M., Al-Masri O.A., Chaudry N.C., Kazkaz G.A. Cetuximab-based Therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung 2011, 189:193-198.
29. 2013. http://newsroom.lilly.com/releasedetail.cfm%3FReleaseID=784772.
30. Paz-Ares L., Mezger J., Ciuleanu T., Fischer J.R., Von Pawel J., Provencio M., et al. Randomized phase-3 trial (INSPIRE) of necitumumab plus cisplatin-pemetrexed versus cisplatin-pemetrexed alone as first-line therapy in stage IV non-squamous NSCLC. 15th World Conference on Lung Cancer, October 27-31 2013, [abstract O03.02].
31. Pirker R., Pereira J.R., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13:33-42.
32. Dacic S., Flanagan M., Cieply K., Ramalingam S., Luketich J., Belani C., et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006, 125:860-865.
33. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi H., Angeletti C.A., et al. Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995, 31A:178-183.
34. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
35. Ohsaki Y., Tanno S., Fujita Y., Toyoshima E., Fujiuchi S., Nishigaki Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000, 7:603-607.
36. Parra H.S., Cavina R., Latteri F., Zucali P.A., Campagnoli E., Morenghi E., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004, 91:208-212.
37. Veale D., Ashcroft T., Marsh C., Gibson G.J., Harris A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987, 55:513-516.
38. Wang L., Chen Y.Z., Shi D., Shi X.Y., Zou Z., Zhao J.H. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis. Drugs Res Dev 2011, 11:317-326.
39. Redman M.W., Crowley J.J., Herbst R.S., Hirsch F.R., Gandara D.R. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012, 18:4004-4012.